The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

I write highly abstracted programs that need to basically define themselves at runtime, rather than designtime, so that wasn't going to work. Off to writing a JSON parser.

Recursion acquires full interest in Rallybio's ENPP1 inhibitor program to develop a potential oral treatment for hypophosphatasia.

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...